Patient-Specific Intelligence for Safer CAR-T Therapy
Predict. Prepare. Personalize to manage
DAR-T brings human biology, patient-derived cellular systems, and AI-enabled biological intelligence together to generate structured insights into major CAR-T treatment-associated toxicities, including Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and Cardiovascular Toxicity
Option to get an individualized toxicity-risk report — before treatment begins
Give the treating team more patient-specific biological information before CAR-T infusion
From Population-Level Risk to Patient-Specific Biology
Traditional CAR-T toxicity management depends substantially on population-level clinical experience, baseline patient assessment,
and post-infusion surveillance as adverse event reports
Assess Key CAR-T Treatment-Associated Toxicities with Patient-Specific Intelligence
CRS
Cytokine Release Syndrome Identify biological markere associated with potentially severe CRS
ICANS
Immune Effector Cell-Associated Neurotoxicity Syndrome - assess neurotoxicity risk using patient-derived biological insights
Cardiovascular Toxicity
Cardiovascular Toxicity evaluate potential cardiovascular risk before treatment
Designed Around the Treating Physician
DAR-T is intended to complement—not replace—clinical judgement
DAR-T is designed for engagement with
Potential implementation models include centralized testing through Transcell Biologics, hospital-linked laboratory workflows, and supportive clinical validation programs